Nkarta
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2015-01-01
- Employees
- 150
- Market Cap
- $379.6M
- Website
- http://www.nkartatx.com
- Introduction
Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The firm’s product include NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes, and NKX01...
NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Participants With Immune-Mediated Diseases (Ntrust-2)
- Conditions
- Interventions
- First Posted Date
- 2024-12-13
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Nkarta, Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT06733935
- Locations
- 🇺🇸
HMH Hackensack University Medical Center, Hackensack, New Jersey, United States
NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With Autoimmune Disease (Ntrust-1)
- Conditions
- Interventions
- First Posted Date
- 2024-08-16
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Nkarta, Inc.
- Target Recruit Count
- 21
- Registration Number
- NCT06557265
- Locations
- 🇺🇸
University of Massachusetts, Worcester, Massachusetts, United States
🇺🇸Emory University, Atlanta, Georgia, United States
🇺🇸NYU Langone Health, New York, New York, United States
NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers
- First Posted Date
- 2021-08-25
- Last Posted Date
- 2024-03-21
- Lead Sponsor
- Nkarta, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT05020678
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇦🇺Institute of Haematology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
🇺🇸The Cleveland Clinic Foundation, Cleveland, Ohio, United States
NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS
- Conditions
- Interventions
- First Posted Date
- 2020-11-10
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- Nkarta, Inc.
- Target Recruit Count
- 61
- Registration Number
- NCT04623944
- Locations
- 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸MD Anderson Cancer Center, University of Texas, Houston, Texas, United States
🇺🇸Colorado Blood Cancer Institute, Denver, Colorado, United States